Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Empresa francesa busca un socio para desarrollar conjuntamente una molécula pequeña contra el cáncer

Resumen

Tipo:
Demanda Tecnológica
Referencia:
TRFR20170807001
Publicado:
01/09/2017
Caducidad:
01/09/2018
Resumen:
Una empresa francesa está desarrollando una nueva molécula que se emplea como primera o segunda línea en el tratamiento de cánceres quimiorresistentes. Esta pequeña molécula es altamente específica y citotóxica para células cancerosas a nivel nanomolar, y tiene un mecanismo de acción secuencial sinérgico en tres pasos: inhibición de la maquinaria de traslación en células cancerosas, arresto del ciclo celular y activación de la apoptosis, y activación de respuestas mediadas por interferona, que sostienen la apoptosis. La empresa busca socios en las industrias biotecnológica y farmacéutica con experiencia complementaria para establecer acuerdos de cooperación técnica.

Details

Tittle:
A French company is looking for a co-development agreement for its anti cancer small molecule
Summary:
A French company is developing a novel molecule to be used as a first or second line in the treatment of chemoresistant cancers.

The company is looking for technical cooperation agreements with biotech and pharmaceutical partners with complementary expertise.
Description:
The French company develops new, first-in-class drugs that meet unfulfilled medical needs in the fields of oncology and inflammatory diseases and notably for indications of rare diseases.

The activity is based on acquiring licensing options for technologies at an early stage of development, following the detection and early co-maturation of innovative projects derived from Universities, and then develop the technology until reaching clinical phase I/IIA and license-out to a Pharmaceutical company.

The company is developing a first-in-class new chemical entity (NCE), small molecule, which is highly specific and cytotoxic for cancer cells (nanomolar level). It has a 3-step synergic sequential mechanism of action (3 in 1 moiety):

1 - Inhibition of the translation machinery in cancer cells;
2 - Cell cycle arrest and apoptosis activation;
3 - Activation of interferon-mediated responses, sustaining apoptosis.

The company intends to develop it as a novel treatment to be integrated in the arsenal of drugs for first or second line of treatment for chemoresistant tumors, to be used alone or in combination with other drugs or within an antibody-drug conjugate (ADC) strategy.
Technical Specification or Expertise Sought:
The company is looking for:
- all-size biotech and pharmaceutical partners with a complementary expertise in oncology drug development, in order to support the preclinical development of the anti-cancer small molecule via a co-development agreement.

Partner sought

Type and Role of Partner Sought:
We are open to co-development agreement with Biotech/Pharma partner.

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
French